MNCs Continue Patent Filings In India Despite Strong Local Challenges
This article was originally published in PharmAsia News
Executive Summary
Multinational pharmaceutical companies continue to file for Indian drug patents despite strong challenges waged by local drug makers. Many of the new filings are for drugs in the same class as Gleevec (imatinib mesylate) a Novartis drug the subject of a long-lasting court fight. AstraZeneca, Bayer, Bristol Myers Squibb, GlaxoSmithKline and Pfizer have filed applications for six drugs considered a new generation of medicines in the same class as Gleevec for treating chronic myeloid leukemia. For instance, Novartis has filed for a patent for Tasigna (nilotinib monohydrate) to treat patients resistant or tolerant to Gleevec. (Click here for more
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.